OBJECTIVES: We sought to examine the effect of atorvastatin therapy on exercise leg blood flow in healthy middle-aged and older-men and women. BACKGROUND: The vasodilatory response to exercise decreases in humans with aging and disease and this reduction may contribute to reduced exercise capacity. METHODS: We used a double-blind, randomly assigned, placebo-controlled protocol to assess the effect of atorvastatin treatment on exercising leg hemodynamics. We measured femoral artery blood flow (FBF) using Doppler ultrasound and calculated femoral vascular conductance (FVC) from brachial mean arterial pressure (MAP) before and during single knee-extensor exercise in healthy adults (ages 40-71) before (PRE) and after (POST) 6 months of 80 mgatorvastatin (A: 14 men, 16 women) orplacebo (P: 14 men, 22 women) treatment. FBF and FVC were normalized to exercise power output and estimated quadriceps muscle mass. RESULTS:Atorvastatin reduced LDL cholesterol by approximately 50%, but not in the placebo group (p < 0.01). Atorvastatin also increased exercise FBF from 44.2 ± 19.0 to 51.4 ± 22.0 mL/min/W/kg muscle whereas FBF in the placebo group was unchanged (40.1 ± 16.0 vs. 39.5 ± 16.1) (p < 0.01). FVC also increased with atorvastatin from 0.5 ± 0.2 to 0.6 ± 0.2 mL/min/mmHg/W/kg muscle, but not in the placebo subjects (P: 0.4 ± 0.2 vs. 0.4 ± 0.2) (p < 0.01). CONCLUSIONS: High-dose atorvastatin augments exercising leg hyperemia. Statins may mitigate reductions in the exercise vasodilatory response in humans that are associated with aging and disease.
RCT Entities:
OBJECTIVES: We sought to examine the effect of atorvastatin therapy on exercise leg blood flow in healthy middle-aged and older-men and women. BACKGROUND: The vasodilatory response to exercise decreases in humans with aging and disease and this reduction may contribute to reduced exercise capacity. METHODS: We used a double-blind, randomly assigned, placebo-controlled protocol to assess the effect of atorvastatin treatment on exercising leg hemodynamics. We measured femoral artery blood flow (FBF) using Doppler ultrasound and calculated femoral vascular conductance (FVC) from brachial mean arterial pressure (MAP) before and during single knee-extensor exercise in healthy adults (ages 40-71) before (PRE) and after (POST) 6 months of 80 mg atorvastatin (A: 14 men, 16 women) or placebo (P: 14 men, 22 women) treatment. FBF and FVC were normalized to exercise power output and estimated quadriceps muscle mass. RESULTS:Atorvastatin reduced LDL cholesterol by approximately 50%, but not in the placebo group (p < 0.01). Atorvastatin also increased exercise FBF from 44.2 ± 19.0 to 51.4 ± 22.0 mL/min/W/kg muscle whereas FBF in the placebo group was unchanged (40.1 ± 16.0 vs. 39.5 ± 16.1) (p < 0.01). FVC also increased with atorvastatin from 0.5 ± 0.2 to 0.6 ± 0.2 mL/min/mmHg/W/kg muscle, but not in the placebo subjects (P: 0.4 ± 0.2 vs. 0.4 ± 0.2) (p < 0.01). CONCLUSIONS: High-dose atorvastatin augments exercising leg hyperemia. Statins may mitigate reductions in the exercise vasodilatory response in humans that are associated with aging and disease.
Authors: Gualberto Ruaño; Paul D Thompson; Andreas Windemuth; Andrew Smith; Mohan Kocherla; Theodore R Holford; Richard Seip; Alan Hb Wu Journal: Pharmacogenomics Date: 2005-12 Impact factor: 2.533
Authors: Patrick Meijer; Constantijn W Wouters; Petra H H van den Broek; Maarten de Rooij; Gert Jan Scheffer; Paul Smits; Gerard A Rongen Journal: Hypertension Date: 2010-08-02 Impact factor: 10.190
Authors: Paul D Thompson; Beth A Parker; Priscilla M Clarkson; Linda S Pescatello; C Michael White; Adam S Grimaldi; Benjamin D Levine; Ronald G Haller; Eric P Hoffman Journal: Prev Cardiol Date: 2010
Authors: B Delia Johnson; C Noel Bairey Merz; Glenn D Braunstein; Sarah L Berga; Vera Bittner; T Keta Hodgson; Gretchen L Gierach; Steven E Reis; Diane A Vido; Barry L Sharaf; Karen M Smith; George Sopko; Sheryl F Kelsey Journal: J Womens Health (Larchmt) Date: 2004-10 Impact factor: 2.681
Authors: Samuel J Ridout; Beth A Parker; Sandra L Smithmyer; Joaquin U Gonzales; Kenneth C Beck; David N Proctor Journal: J Appl Physiol (1985) Date: 2009-12-03
Authors: D N Proctor; P H Shen; N M Dietz; T J Eickhoff; L A Lawler; E J Ebersold; D L Loeffler; M J Joyner Journal: J Appl Physiol (1985) Date: 1998-07
Authors: Marc E Gomes; Jacques W M Lenders; Louise Bellersen; Freek W A Verheugt; Paul Smits; Cees J Tack Journal: Clin Auton Res Date: 2009-12-04 Impact factor: 4.435
Authors: Muhammad Ismail Shawish; Bahador Bagheri; Vijaya M Musini; Stephen P Adams; James M Wright Journal: Cochrane Database Syst Rev Date: 2021-01-22